Literature DB >> 32105648

Structural approaches to pathway-specific antimicrobial agents.

Michael E Johnson1, Leslie W-M Fung2.   

Abstract

This perspective provides an overview of the evolution of antibiotic discovery from a largely phenotypic-based effort, through an intensive structure-based design focus, to a more holistic approach today. The current focus on antibiotic development incorporates assay and discovery conditions that replicate the host environment as much as feasible. They also incorporate several strategies, including target identification and validation within the whole cell environment, a variety of target deconvolution methods, and continued refinement of structure-based design approaches.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32105648      PMCID: PMC7293926          DOI: 10.1016/j.trsl.2020.02.001

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  77 in total

1.  In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea.

Authors:  Jong Hwa Yum; Chang Ki Kim; Dongeun Yong; Kyungwon Lee; Yunsop Chong; Cheol Min Kim; Jeong Mi Kim; Seonggu Ro; Joong Myung Cho
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

2.  Metabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.

Authors:  Yan-Yan Zhang; Yong Liu; Shahila Mehboob; Jin-Hua Song; Teuta Boci; Michael E Johnson; Arun K Ghosh; Hyunyoung Jeong
Journal:  Xenobiotica       Date:  2013-10-30       Impact factor: 1.908

Review 3.  Exogenous fatty acid metabolism in bacteria.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochimie       Date:  2017-06-28       Impact factor: 4.079

4.  Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria.

Authors:  D A Leigh; K Bradnock; J M Marriner
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

5.  The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.

Authors:  Luke C Kingry; Jason E Cummings; Kerry W Brookman; Gopal R Bommineni; Peter J Tonge; Richard A Slayden
Journal:  J Bacteriol       Date:  2012-11-09       Impact factor: 3.490

6.  Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.

Authors:  Carla Neckles; Sandra Eltschkner; Jason E Cummings; Maria Hirschbeck; Fereidoon Daryaee; Gopal R Bommineni; Zhuo Zhang; Lauren Spagnuolo; Weixuan Yu; Shabnam Davoodi; Richard A Slayden; Caroline Kisker; Peter J Tonge
Journal:  Biochemistry       Date:  2017-03-21       Impact factor: 3.162

Review 7.  Bacterial fatty acid metabolism in modern antibiotic discovery.

Authors:  Jiangwei Yao; Charles O Rock
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-23       Impact factor: 4.698

8.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

9.  Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.

Authors:  Johannes Schiebel; Andrew Chang; Sonam Shah; Yang Lu; Li Liu; Pan Pan; Maria W Hirschbeck; Mona Tareilus; Sandra Eltschkner; Weixuan Yu; Jason E Cummings; Susan E Knudson; Gopal R Bommineni; Stephen G Walker; Richard A Slayden; Christoph A Sotriffer; Peter J Tonge; Caroline Kisker
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

Review 10.  Next-generation antimicrobials: from chemical biology to first-in-class drugs.

Authors:  Michelle Lay Teng Ang; Paul Murima; Kevin Pethe
Journal:  Arch Pharm Res       Date:  2015-08-11       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.